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Y-mazeAbstract The leaves of Spondias mombin L. (Anacardiaceae) when chewed with Cola acuminata (P.
Beauv.) Schott & Endl. (Sterculiaceae) seeds have memory enhancing and anti-ageing properties.
This study sought to investigate the protective effect of hydroethanolic leaf extract of Spondias mom-
bin (SM) and Cola acuminata seed extract (CA) against scopolamine-induced cognitive dysfunction.
SM or CA (50, 100 or 200 mg/kg, p.o.) or SM + CA (50 mg/kg, p.o.) was administered to rats for 3
consecutive days. One hour post-treatment on day 3, scopolamine (3 mg/kg i.p) was administered
and 5 min later, the Y-maze test or Morris water maze test (MWM; days 3–7) was conducted.
The rat’s brains were isolated for the estimation of oxidative-nitritive stress status following the
MWM task. The antioxidant capacity of SM and CA was also evaluated in vitro using the 1,1-
diphenyl-2-picrylhydrazyl (DPPH), nitric oxide (NO) and ferric ion reducing power (FRAP) assays.
Pretreatment of rats with SM, CA or SM + CA significantly ameliorated the learning and memory
impairment induced with scopolamine as evidenced in Y-maze and MWM paradigms. Moreover,
SM, CA or SM + CA significantly attenuated the oxidative-nitritive stress induced by scopolamine,
evidenced in the decrease in malondialdehyde and nitrite levels and restoration of glutathione, cata-
lase and superoxide dismutase levels. Furthermore, SM and CA showed promising free radical scav-
enging effect against DPPH and moderate antioxidant activity in NO and FRAP tests. This study
showed that Spondias mombin and Cola acuminata have significant protective effect against
scopolamine-induced memory deficit that could be attributed to their antioxidant properties.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dementia is a clinical syndrome caused by neurodegeneration
and Alzheimer’s disease (AD) being the most common, charac-
terized by inexorably progressive deterioration in cognitive
ability and capacity for independent living. AD is associated
with the presence of intracellular neurofibrillary tangles and
28 I.O. Ishola et al.extracellular amyloid-b plaques, loss of neuronal subpopula-
tions, synaptophysin immunoreactivity of presynaptic termi-
nals, loss of cholinergic fibres, mitochondrial dysfunction and
proliferation of reactive astrocytes in the entorhinal cortex, hip-
pocampus, prefrontal cortex and amygdala.1,2 Extensive evi-
dence indicates that disruption of cholinergic function is
characteristic of ageing and AD, and experimental manipula-
tion of the cholinergic system in laboratory animals suggests
that age-related cholinergic dysfunction may play an important
role in cognitive deterioration associated with ageing and AD.3
Impaired cortical cholinergic neurotransmission may also con-
tribute to b-amyloid plaque pathology and increase phosphory-
lation of tau protein, the main component of neurofibrillary
tangles in AD4. The restoration of cholinergic function through
prolongation of the availability of acetylcholine (ACh) released
into the neuronal synaptic cleft by inhibiting acetyl-
cholinesterase (AChE) activity, remains a rational target in
the treatment of AD. Acetylcholinesterase inhibitors (tacrine,
donepezil, and rivastigmine) are the mainstay in the treatment
of AD, though effective but not without adverse effects.5,6
Scopolamine (muscarinic cholinergic receptor antagonist)
impaired learning and memory, thus, used extensively to
screen for potential antidementic drugs.7,8 Several post-
mortem and in vivo studies have demonstrated an accumula-
tion of the products of reactive oxygen species (ROS) or
reactive nitrogen species (RNS) damage in AD and scopo-
lamine treated subjects; these substances can be considered
biomarkers of oxidative and nitrosative damage, respec-
tively.9–11 Increased level of malondialdehyde (MDA) is a very
reliable index of in vivo lipid peroxidation.12 On the other
hand, glutathione (GSH) (redox regulator in the maintenance
of oxidant homeostasis and cellular detoxification of ROS in
brain cells) depletion has been shown to affect mitochondrial
function.13 Thus, enhanced expression/activity of the endoge-
nous antioxidant enzymes such as superoxide dismutase
(SOD), catalase and GSH have been used as an index of brain
oxidative stress.12,14 Therefore, supplementation with antioxi-
dants may delay the development of AD, and attenuate neu-
ronal cell death induced by oxidative stress.8,15
Spondias mombin L. (Anacardiaceae) is a fructiferous tree,
native to Nigeria, Brazil and several other tropical forests in
the world and can reach a height of 15–22 m. A decoction of
the mashed leaves with lemon is effective for worms in children
and believed to expel calcifications from the bladder.16 A tea
made from the flowers and leaves is taken to relieve stomach
ache, biliousness, urethritis, cystitis and eye and throat inflam-
mations.17 In Belize, a decoction of the young leaves is a
remedy for diarrhoea and dysentery.18 Interestingly, the
antimicrobial,19 sedative, antiepileptic, and antipsychotic
properties20 of Spondias mombin leaf extract have been
reported. In an ethnobotanical survey by Elufioye et al.21 they
showed that the leaves of Spondias mombin when chewed with
Cola acuminata (P. Beauv.) Schott & Endl. (Sterculiaceae)
seeds have memory enhancing and anti-ageing properties.
C. acuminata is a bitter brown seed found in the pod of
evergreen trees native to Africa, commonly used stimulant in
Nigeria, and has been reportedly used for the management
of memory loss and other neurodegenerative diseases in
folklore.22 Niemenak et al.23 reported that caffeine and
theobromine were the major purine alkaloids in C. acuminata
seeds while catechin and epicatechin were the predominant
polyphenols. Oboh et al.24 also reported anticholinesterase(anti-AChE) and anti-butyrylcholinesterase (anti-BuChE)
activities of C. acuminata seed extract with median inhibitory
concentrations (IC50) of 14.60 and 96.20 lg/mL, respectively,
in a dose-dependent manner. In this study, we examined the
effect of S. mombin and C. acuminata on memory processes
and oxidative stress status in the prefrontal cortex, striatum
and hippocampus of scopolamine-treated animals.2. Materials and methods
2.1. Plant material
The leaves of S. mombin were collected from Abatadu, Osun
state, Nigeria, in May 2015 and seeds of C. acuminata were
purchased from Mushin Herbal Market, Lagos state, Nigeria.
The Botanical identification and authentication were done by
Mr. Oyebanji, Department of Botany and Microbiology,
University of Lagos, Akoka, Lagos state, Nigeria. The Vou-
cher Specimens: LUH 6511 (Spondias mombin) and LUH
6905 (Cola acuminata) were deposited in the Herbarium of
the Department for reference purposes.
2.2. Laboratory animals
Male Sprague-Dawley rats (150–170 g) and female Swiss
albino mice (18–22 g) used in this study were obtained from
the Laboratory Animal Centre, College of Medicine, Univer-
sity of Lagos, Lagos, Nigeria. The animals were housed six
per cage, allowed access to water and food (Livestock Feeds,
Lagos, Nigeria) ad libitum, and maintained at a constant tem-
perature (23 C ± 1 C) and humidity (60%± 10%) under a
12-h light/dark cycle (light on 07:00–19:00 h). The animals
were maintained under laboratory conditions for an acclimati-
zation period of 7 days before performing the experiment. Ani-
mal maintenance and treatment were carried out in accordance
with the United States, National Institutes of Health Guideli-
nes for Care and Use of Laboratory Animals in Biomedical
Research (2011).
2.3. Preparation of the extract
The air-dried leaves of S. mombin were pulverized into powder
(356 g). The powdered leaf was soaked in 6.25 L of 70% etha-
nol for 72 h at room temperature with intermittent agitation.
The extract was filtered and the filtrate obtained was concen-
trated by Heidolph Rotavapor (Switzerland) at 40 C, and
further oven-dried at 40 C to give a deep green extract with
a yield of 19 g (5.34% w/w).
The seeds of C. acuminata (2870 g) were chopped into small
pieces and air-dried for 7 days. The dried seeds were pulverized
into fine powder. The powdered seeds (1441 g) were soaked in
3.25 L of 70% ethanol for 72 h. The extract was filtered and
the filtrate obtained was concentrated by Heidolph Rotava-
por (Switzerland) at 40 C, and further oven-dried at 40 C to
give a deep brown extract with a yield of 149 g (10.34% w/w).
2.4. Drugs and chemicals
Ethanol, chloral hydrate, tacrine, glacial acetic acid, Folin-
Ciocalteu reagent, scopolamine hydrobromide, phosphate buf-
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hydroxide, potassium ferricyanide, trichloroacetic acid,
napthylethylenediamine dihydrochloride, ferric chloride,
DPPH solution, dithio-bis-nitrobenzoic acid (DTNB), and
bovine serum albumin were purchased from Sigma Aldrich,
St. Louis MO, USA, while normal saline was purchased from
Unique Pharmaceutical Ltd, Lagos, Nigeria.
2.5. Quantitative phytochemical estimation and antioxidant
capacity
2.5.1. Determination of total phenolic content
Total phenolic content of CA or SM was determined using
Folin-Ciocalteu reagent as described by Velioglu et al.25 with
slight modifications. The total phenolic content of CA or
SM was estimated using Folin-Ciocalteu reagent with gallic
acid as a standard. Briefly, 12.5 lL of CA, SM or gallic acid
(0–100 mg/ml) was mixed with 12.5 lL of Folin-Ciocalteu
reagent. Five minutes later, 12.5 lL of saturated sodium car-
bonate (NaCO3) solution (7%) was added to the reaction mix-
ture. The reaction mixtures were incubated at room
temperature for 90 min and the absorbance was recorded at
725 nm. Ethanol was used as a blank. A dose response linear
regression was generated by using the gallic acid standard
absorbance and the levels in the samples were expressed as gal-
lic acid equivalents (mg of GAEs/mg dry weight).
2.5.2. Assay for total flavonoid content
The total flavonoid content was determined spectrophotomet-
rically according to the method previously described by
Kumaran and Karunakaran.26 One millilitre of the extracts
in ethanol (200 lg/ml) was mixed with 1 ml of aluminium
trichloride in ethanol (20 mg/ml). The absorbance values of
the reaction mixtures were read at 415 nm after 10 min against
a blank. Rutin was used as the standard and the total flavo-
noid content of the extracts was expressed as mg of rutin
equivalent per gram of dry extract (mg RE/g of dry extract).
2.5.3. Assay for total antioxidant capacity
The antioxidant activity of CA or SM was evaluated by the
phosphomolybdenum method in accordance with the proce-
dure described by Prieto et al.27 The assay is based on the
reduction of Mo (VI) to Mo (V) by the extract and subsequent
formation of a green phosphate/Mo (V) complex at an acidic
pH. CA or SM (0.3 ml) was mixed with 3 ml of reagent solu-
tion (0.6 M sulphuric acid, 28 mM sodium phosphate, and
4 mM ammonium molybdate). Test tubes containing the reac-
tion solution were incubated at 95 C for 90 min. The absor-
bance was read at 695 nm. The total antioxidant capacities
were expressed as mg gallic acid equivalent per g dry extract.
2.6. In vitro evaluation of antioxidant activities
2.6.1. 1,1-Diphenyl-2-picrylhydrazyl (DPPH) free radical
scavenging activity
The free radical scavenging potential of the extracts was deter-
mined according to the procedure of Awah et al.28 with some
minor modifications. Briefly, an aliquot of 50 lL of CA or SM
(10–100 lg/ml) was mixed with 950 lL of ethanolic solution of
DPPH (3.4 mg/100 ml). The mixture was vortexed and incu-bated in the dark at 37 C for 1 h. The free radical scavenging
potential of CA or SM was expressed as the disappearance of
the initial purple colour. The absorbance of the reaction mix-
ture was recorded at 517 nm using a UV–Visible spectropho-
tometer (Agilent 8453, Germany). Gallic acid was used as
the positive control. The percentage inhibition of DPPH free
radical was calculated according to the formula:
% Inhibition¼Absorbance of controlAbsorbance of sample
Absorbance of control
 1002.6.2. Assay for nitric oxide scavenging activity
Sodium nitroprusside is known to decompose in an aqueous
solution at physiological pH (7.2) producing NO*. Under aer-
obic condition, NO reacts with oxygen to produce stable prod-
ucts (nitrite and nitrate). The effect of CA or SM on nitrite
generation was evaluated using the Griess reagent as modified
by Mirkov et al.29 Griess reagent consists of sulphanilamide
(1%), naphthylethylene diamine dihydrochloride (2%) and
H3PO4 (0.1%). Briefly, 4 ml of CA or SM (10–100 lg/mL)
was mixed with 1 ml of 5 mM sodium nitroprusside in phos-
phate buffer saline (PBS) at pH 7.4. The reaction mixture
was incubated for 2 h at room temperature (31 C). Two millil-
itres of the CA or SM reaction mixture or standard nitrite was
mixed with 1.2 ml of Griess reagent and the absorbance of the
reaction mixture was measured at 550 nm. The phosphate buf-
fered saline was used as a blank. The concentration of nitrite
was calculated with reference to the absorbance of the stan-
dard nitrite. The percentage inhibition was calculated accord-
ing to the following:
½ðA0  A1Þ  100=A0:
where A0 = absorbance of standard, A1 = absorbance of the
extracts.
2.6.3. Ferric ion reducing power assay
The reducing capacity of CA or SM may serve as a good indi-
cator of its potential antioxidant property. The reducing power
of CA or SM was investigated using the method of Oyaizu.30
Various concentrations of CA, SM or gallic acid solution
(1.0 ml) were mixed with 2.5 ml of potassium buffer (0.2 M,
pH 6.6) and 2.5 ml of potassium ferricyanide [K3Fe(CN)6]
(1% w/v). After 30 min of incubation at 50 C, 2.5 ml of
10% trichloroacetic acid solution was added to each test tube
and the mixture was centrifuged at 10,000g for 10 min. Then,
2.5 ml of the supernatant solution was withdrawn from the
tube and mixed with 2.5 ml of distilled water and 0.5 ml of fer-
ric chloride solution (0.1%, w/v). The absorbance was mea-
sured at 700 nm.
2.7. Acute toxicity test
The acute toxicity of CA or SM was determined using the fixed
dose protocol of the Organization of Economic Co-operation
and Development (OECD) guidelines for testing of chemicals,
TG420 (OECD, 2001) for oral administration. 22 female mice
were given CA or SM (250 mg/kg, p.o., n = 1; 2500 mg/kg,
p.o., n = 5; and 5000 mg/kg, p.o., n= 5). Behavioural signs
of toxicity and mortality were observed; during the first








SM 29.28 ± 0.11 41.06 ± 0.17 12.84 ± 0.16
CA 35.48 ± 0.28 60.13 ± 0.11 16.44 ± 0.12
Values are expressed as mean ± S.D (n = 3), TPC (total phenolic
content), TAC (total antioxidant capacity), TFC (total flavonoid
content), GAE (gallic acid equivalent), AE (ascorbic acid equiva-
lent), RE (rutin equivalent), DE (dry extract).
Table 2 Free radical scavenging, nitric oxide inhibition and







SM 46.78 ± 1.89 37.94 ± 1.09 96.13 ± 4.32
CA 56.50 ± 2.75 47.07 ± 3.11 106.50 ± 3.74
Ascorbic acid 41.41 ± 3.56 40.74 ± 1.28 64.11 ± 4.75
Values are expressed as mean ± S.D (n= 3).
30 I.O. Ishola et al.30 min, then the second, fourth, sixth hour and once daily for
14 days for delayed toxicity or mortality. Also, the effect of the
extracts on spontaneous locomotor activity was observed
using the open field test.31
2.8. Behavioural cognition tests
2.8.1. Y-maze test
The test relies on the innate tendency of rats to explore a novel
environment to assess spatial recognition. Rats (150–170 g)
were randomly divided into 10 groups (n = 6) and treated as
follows for 3 days: Group 1-vehicle (10 ml/kg; p.o., normal
control), Group 2-vehicle (10 ml/kg, p.o., amnesic model),
Group 3-tacrine (5 mg/kg; i.p.), Groups 4–6: CA (50, 100
and 200 mg/kg; p.o., respectively), Groups 7–9: SM (50, 100
and 200 mg/kg; p.o., respectively) or Group 10: SM+ CA
(50 mg/kg; 1:1 dilution). One hour after vehicle or drug admin-
istration on day 3, scopolamine (3 mg/kg, i.p.) was adminis-
tered to rats in Groups, 2–10. Five minutes post-scopolamine
injection, cognitive function of the rat was evaluated by plac-
ing it in the centre of the Y-maze facing the south arm ‘B’
and allowing it to explore the maze freely for a period of
5 min. The number and the sequence of arm entries were
observed. An arm entry was scored when all four paws were
in the arm. Alternation behaviour was defined as consecutive
entries into all three arms (i.e., ABC, CAB, or BCA but not
BAB).32 The percentage of spontaneous alternation was mea-
sured as an index of working memory by calculating the ratio
of the actual number of alternations to the possible number
(defined as the total number of arm entries minus two) multi-
plied by 100, i.e., % alternation [(number of alternations)/(to-
tal number of arm entries – 2)]  100. The total number of arm
entries was recorded as an index of locomotor activity.
2.8.2. Morris water maze (MWM) test
Male albino rats were randomly divided into 10 groups (n = 6)
and treated as follows for 3 consecutive days: Group 1-vehicle
(10 ml/kg; p.o., normal control), Group 2-vehicle (10 ml/kg, p.
o., amnesic model), Group 3-tacrine (5 mg/kg; i.p.), Groups 4–
6: CA (50, 100 and 200 mg/kg; p.o., respectively), Groups 7–9:
SM (50, 100 and 200 mg/kg; p.o., respectively) or Group 10:
SM+ CA (50 mg/kg; 1:1 dilution). One hour after vehicle or
drug administration on day 3 of treatment, scopolamine
(3 mg/kg, i.p.) was administered to rats in Groups, 2–10. Five
minutes post-scopolamine injection, spatial learning was eval-
uated using the Morris water maze task for 5 consecutive days
(days 3–7). The MWM apparatus consisted of a circular water
tank (110 cm diameter and 60 cm height) filled with water (26
± 2 C) to a depth of 30 cm. Four equally spaced points
around the edge of the pool were designated as N (North), E
(East), W (West), and S (South). A black round platform of
diameter 10 cm was placed 2 cm below the surface of the water
in a constant position in the middle of the southwest quadrant
in all trials. The rats were given a maximum of 60 s (cut-off
time) to locate the hidden platform and were allowed to stay
on it for 10 s. The time taken for the rat to locate the escape
platform was recorded using a stopwatch. In the event that
the animal was unable to locate the hidden platform within
60 s, it was gently guided to it and was allowed to stay on it
for 10 s. Each rat was subjected to a daily session of 3 trials
per day for 5 days consecutively. Escape latency time (ELT)(time to locate the hidden platform in the water maze) was
used as an index of learning.8,33
2.9. Brain tissue preparation
After the MWM test on day 7, all the rats were anaesthetized
with chloral hydrate (300 mg/kg, i.p.) and rapidly perfused
with cold chilled normal saline. The skull was cut open and
the brain was exposed from its dorsal side. The whole brain
was quickly removed and the prefrontal cortex (PFC), stria-
tum (STR) and hippocampus (HIP) were isolated on an ice-
cold plate. The isolated brain areas were weighed and homog-
enized in 0.03 M sodium phosphate buffer, pH-7.4 with an
Ultra-Turrax T25 (LA, USA) homogenizer at a speed of
9500 rpm. The homogenate was used to assay for malondialde-
hyde (MDA), reduced glutathione (GSH), superoxide dismu-
tase (SOD), and nitrite.
2.10. Biochemical estimations
2.10.1. Estimation of MDA level
MDA, which is an indicator of lipid peroxidation, was spec-
trophotometrically measured using the thiobarbituric acid
assay procedure.8 Two hundred microlitres of supernatant
was added and briefly mixed with 1 mL of 50% trichloroacetic
acid in 0.1 M HCl and 1 mL of 26 mM thiobarbituric acid.
After mixing on a vortex, samples were maintained at 95 C
for 20 min, after which samples were centrifuged at 960g for
10 min and supernatants were read at 532 nm. The results were
expressed as U/mg protein.
2.10.2. Measurement of GSH
GSH was determined by its reaction with 5,50-dithiobis (2-
nitrobenzoic acid) (Ellman’s reagent) to yield a yellow chro-
Table 3 Effect of SM and CA on spontaneous locomotor activity.
Treatment (mg/kg) Line crosses Rearing Grooming
Vehicle 10 ml/kg 67.40 ± 13.77 19.80 ± 4.59 7.80 ± 2.48
SM 5000 65.20 ± 4.31 7.20 ± 1.80** 4.60 ± 1.97*
CA 5000 75.20 ± 13.75 18.80 ± 4.86 10.80 ± 5.14
Values are expressed in mean ± SEM (n= 5).
* P < 0.05.
** P < 0.01 versus vehicle treated control (one way ANOVA followed by Tukey post hoc multiple comparison test).
Cognitive enhancing effect of Spondias mombin and Cola acuminata 31mophore which was measured spectrophotometrically.7 The
brain homogenate was mixed with an equal amount of 10%
trichloroacetic acid (TCA) and centrifuged (Remi cold cen-
trifuge) at 2000g for 10 min at 4 C. The supernatant was used
for GSH estimation. To 100 ll of processed tissue sample, 2 ml
of phosphate buffer (pH 8.4), 0.5 ml of 5,50-dithiobis (2-
Nitrobenzoic acid) (DTNB) and 0.4 ml of double-distilled
water were added and the mixture was shaken vigorously on
a vortex mixer. The absorbance was read at 412 nm within
15 min. The results were expressed as U/mg protein.
2.10.3. Determination of catalase activity
Catalase (CAT) activity was assayed according to the method
of Sinha.34 Twenty-five microlitre aliquots of the supernatant























































































Figure 1 Effect of (A) SM or (B) CA on spontaneous alternation
behaviour in scopolamine-treated mice in the Y-maze test. Values
are expressed as mean ± SEM (n= 6), **P < 0.01; ***P < 0.001
versus vehicle-treated; aP < 0.05; bP < 0.01; cP < 0.05 versus
scopolamine-treated group (one-way ANOVA followed by Tukey
post hoc multiple comparison test).phate buffer at pH 8.0 and 500 lL of 10 mM H2O2. The reac-
tion was stopped by the addition of 2.0 ml of dichromate-
acetic acid reagent (5% potassium dichromate and glacial
acetic acid were mixed in 1:3 ratio). The decomposition of
H2O2 was directly estimated by the net decrease in absorbance
at 240 nm. The reaction mixture (1.5 ml) contained 1.0 ml of
0.01 M phosphate buffer (pH 7.0), 0.4 ml of 2 M H2O2. The
results were expressed as U/mg protein.
2.10.4. Determination of superoxide dismutase (SOD) activity
The activity of superoxide dismutase (SOD, EC 1.15.1.1) was
assayed according to the method of Winterbourn et al.35 by
monitoring its ability to inhibit the photochemical reduction
in nitroblue-tetrazolium (NBT). Each 1.5 mL reaction mixture




























































Figure 2 Effect of (A) SM and (B) CA on total number of arm
entries in scopolamine-treated mice in the Y-maze. Values are
expressed as mean ± SEM (n= 6).
32 I.O. Ishola et al.riboflavin, 6 mM EDTA, and 200 lL of supernatant. Monitor-
ing the increase in absorbance at 560 nm followed the produc-
tion of blue formazan. One unit of SOD is defined as the
quantity required to inhibit the rate of NBT reduction by
50%. The enzyme activity is expressed as U/mg protein.
2.10.5. Nitrite estimation
Nitrite was estimated in the rat’s brain using the Griess reagent
(an indicator of nitric oxide (NO) production). NO has a short
half-life and is rapidly converted to the stable end products
such as nitrate (NO3
) and nitrite (NO2
). One hundred micro-
litre of Griess reagent (1:1 solution of 1% sulphanilamide in
5% phosphoric acid and 0.1% napthylamine diamine dihy-
drochloric acid in water) was mixed with 100 ll of supernatant
and vortexed. The absorbance was measured at 542 nm.8
Nitrite concentration was calculated using a standard curve
for sodium nitrite.
2.10.6. Protein estimation
Protein was measured in all brain samples by the method of
Lowry et al.36 Bovine serum albumin (BSA) (1 mg/ml) was used



























































Figure 3 Effect of (A) SM and (B) CA on spatial learning following s
test in rats. Values are expressed as mean ELT (s) ± S.E.M (n= 6). aP
followed by Tukey post hoc multiple comparison test).2.11. Statistical analysis
Results obtained are expressed as mean ± SEM (n= 6). The
statistical level of significance was determined by one- or
two-way ANOVA followed by Tukey post hoc multiple com-
parison test (whichever is applicable) using Graphpad prism
version 6 (Graphpad prism Inc, CA, USA).3. Results
3.1. TPC, TFC and TAC
Table 1 lists gallic acid equivalents of total phenolic content of
SM and CA. The phenolic compounds in the extract varied
from 29.28 mg GAE/g DE in SM to 35.48 mg GAE/g DE in
CA. In addition, the total flavonoid contents (major compo-
nents of the phenolic compounds) of SM and CA were esti-
mated, and the total flavonoids ranged from 12.84 to
16.44 mg RE/g DE, in SM and CA, respectively. Moreover,
the extracts showed potent antioxidant capacity ranging from










































copolamine-induced memory impairment in the Morris water maze







































































































































Figure 4 Effect of SM and CA on MDA levels in the (A)
prefrontal cortex, (B) hippocampus and (C) striatum of scopo-
lamine-treated rats after the MWM task. Values are expressed as
Mean ± SEM (n= 6). **P < 0.01, ***P < 0.001 versus vehicle-
treated control, aP < 0.05, bP < 0.01, cP < 0.001 versus vehicle
+ scopolamine treated (one-way ANOVA followed by Tukey post
hoc multiple comparison test).
Cognitive enhancing effect of Spondias mombin and Cola acuminata 3360.13 mg ascorbic acid equivalent per gram of CA extract
(Table 1).
3.2. DPPH, NO and FRAP estimation
The antioxidant activity of SM and CA was assessed by
DPPH, which is based on the ability of DPPH to react with
proton donors such as phenols. SM and CA exhibit DPPH free
radical scavenging potential comparatively similar to the effect
of ascorbic acid (Table 2). In another experiment, the ability of
the extracts to scavenge NO production was evaluated. SM,
CA and ascorbic acid attenuated NO production as shown
in Table 2. In the reducing power assay, SM, CM and ascorbic
acid showed concentration dependent increase in absorbance
indicating high reducing power (Table 2).
3.3. Acute toxicity test
The extract of SM and CA up to 5000 mg/kg did not induce
mortality but the observed toxicity behaviours include restless-
ness and tachypnoea. However, CA caused no significant
change in exploratory behaviour (rearing and grooming) and
locomotor activity (number of lines crosses) as shown in
Table 3. SM on the other hand produced significant change
in rearing (P < 0.01) and grooming (P < 0.05) behaviour
but caused no significant change in locomotor activity
(Table 3).
3.4. Y-maze test
The effects of SM and CA on short-term or working memory
were investigated in the spontaneous alternation behaviour in
Y-maze. One way ANOVA revealed significant effect of treat-
ment on alternation behaviour [F(5,24) = 8.409, P < 0.01].
Post hoc test showed that intraperitoneal administration of
scopolamine induced significant deficit in spontaneous alterna-
tion behaviour when compared with vehicle-treated control
(Fig. 1A). However, pretreatment of rats with SM reversed
the decrease in alternation behaviour induced by scopolamine
which was similar to the effect of tacrine. Similarly, CA (100
and 200 mg/kg) produced significant increase in percentage
alternation behaviour [F(6,28) = 5.103, P < 0.01] when com-
pared with vehicle-scopolamine treated rats (Fig. 1B). Interest-
ingly, the combination of SM and CA (50 mg/kg) increased [F
(6,28) = 5.103, p < 0.01] the spontaneous alternation beha-
viour compared with vehicle-scopolamine treated. However,
in all the treated groups no significant change in the number
of entries was observed (Fig. 2A and B).
3.5. MWM task
Vehicle treated rats quickly acquired the spatial task as
depicted by a gradual session-dependent decrease in escape
latency [F(4,20) = 32.07, P < 0.001]. However, scopolamine
(3 mg/kg, i.p.) administration caused spatial memory impair-
ment as indicated by no significant change [F(4,20) = 5.473,
P < 0.01] in ELT from 2nd to the 5th sessions when compared
with session 1. In contrast, tacrine pretreatment before scopo-
lamine injection, produced a significant decrease [F(4,20)
= 167.5, P < 0.001] in ELT from sessions 2–5 when comparedto session 1. Similarly, oral administration of SM prevented
scopolamine-induced memory impairment, and SM (50, 100
and 200 mg/kg) significantly decreased [F(4,20) = 37.79,
P < 0.001], [F(4,20) = 33.95, P < 0.001], [F(4,15) = 4.31,
P < 0.01] ELT from session 2–5 when compared with session
1 (Fig. 3A). Similarly, CA administration prevented
scopolamine-induced memory impairment in rats. As shown
in Fig. 3B, CA (50, 100 and 200 mg/kg) significantly decreased
[F(4,20) = 34.56, P < 0.001], [F(4,20) = 43.47, P < 0.001],
[F(4,20) = 281.9, P < 0.001] ELT from sessions 2–5 in com-
parison with session 1. The combination of SM 50 mg/kg
and CA 50 mg/kg significantly decreased [F(4,20) = 70.55,
P < 0.001] ELT from sessions 2–5 when compared with
session 1.
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Scopolamine administration significantly increased [F(2,15)
= 35.10, P < 0.001] MDA level in the prefrontal cortex of
rats in comparison with vehicle-treated group. However, treat-
ment with tacrine, significantly decreased [F(4,25) = 3.080,
P < 0.05] MDA levels by 5.6 folds. Similarly, pretreatment
of rats with SM (50 and 200 mg/kg) significantly attenuated
[F(4,25) = 3.080, P < 0.05] MDA generation in comparison
with scopolamine treated group. In the same vein, pretreat-
ment of rats with CA (200 mg/kg) significantly ameliorated
[F(5,30) = 3.179, P < 0.05] MDA levels when compared with
scopolamine-vehicle treated. The combination of SM and CA
(50 mg/kg) significantly decreased [F(5,30) = 3.080, P < 0.05]
MDA level by 7.7 folds in comparison with scopolamine-
vehicle treated group (Fig. 4A). In the hippocampus, scopo-
lamine administration significantly increased [F(2,15) =
35.10, P < 0.001] MDA level by 3.12 folds in comparison with
vehicle-control treated. Interestingly, tacrine and SM treat-
ment showed no significant change in MDA level in compar-
ison with scopolamine treated group. However, CA
treatment at 200 mg/kg as well as the combination of SM
50 mg/kg and CA 50 mg/kg significantly reduced [F(4,25)
= 10.59, P < 0.001] and [F(2,5) = 5.619, P < 0.05] MDA
level by 2.53 and 1.60 folds, respectively, versus
scopolamine-vehicle treated group (Fig. 4B). One way
ANOVA revealed significant effect of scopolamine administra-
tion [F(2,15) = 31.10, P < 0.001]. Post hoc analysis showed
that intraperitoneal administration of scopolamine produced
significant (P < 0.001) increase in MDA levels in the striatum




















































































Figure 5 Effect of SM and CA on GSH level in the (A) prefrontal cor
after the MWM task. Values are expressed as mean ± SEM (n= 6).
bP < 0.01, cP < 0.001 versus vehicle + scopolamine treated (one-wayever, pretreatment of rats with tacrine, SM and CA (50 and
100 mg/kg) failed to reverse the increase in MDA level induced
by scopolamine. On the other hand, pretreatment of rats with
CA (200 mg/kg) significantly reduced [F(3,20) = 9.058,
P < 0.01] MDA levels. The combination of SM 50 mg/kg
and CA 50 mg/kg could not reverse the increase in MDA levels
induced by scopolamine injection (Fig. 4C).
3.7. GSH levels
Scopolamine injection produced significant decrease in the
prefrontal cortex GSH level when compared with vehicle-
treated control group. Conversely, the pretreatment of rats
with SM (100 mg/kg) or CA (50 mg/kg) increased GSH level
[F(4,25) = 3.424, P< 0.05] by 0.56 and 0.46 folds, respec-
tively. However, there was no significant change in the level
of GSH in the prefrontal cortex in combined treatment
groups (Fig. 5A). Scopolamine injection also induced deficit
in GSH level in the hippocampus which was reversed by pre-
treatment of rats with tacrine, SM (50, 100 and 200 mg/kg)
or CA (100 mg/kg) [F(4,25) = 6.182, P < 0.05]. Further-
more, the combination of SM 50 mg/kg and CA 50 mg/kg
synergistically enhanced GSH level in the hippocampus
(Fig. 5B).
One way ANOVA revealed significant effect of treatment
on GSH level in the striatum [F(9,50) = 11.67, P < 0.001].
Post hoc analysis showed that scopolamine injection caused
significant decrease (P < 0.05) in the level of GSH when com-
pared with vehicle control treated. Similarly, tacrine produced
no significant change in the level of GSH in the striatum in









































tex, (B) hippocampus and (C) striatum of scopolamine-treated rats
*P < 0.05, **P < 0.01 versus vehicle-treated control, aP < 0.05,
ANOVA followed by Tukey post hoc multiple comparison test).
Cognitive enhancing effect of Spondias mombin and Cola acuminata 35treatment of rats with SM (50 and 100 mg/kg) (p< 0.001) or
CA (100 mg/kg) (p < 0.001) increased GSH level by 0.59
and 0.57 folds, respectively. Moreover, treatment of rats with
combined doses of SM 50 mg/kg and CA 50 mg/kg increased
(P < 0.001) the level of GSH by 0.55 folds [F(3,20) = 8.858,
















































































Figure 7 Effect of SM and CA on SOD activity in the (A) prefrontal
rats after the MWM task. Values are expressed as mean ± SEM (n= 6














































































Figure 6 Effect of SM and CA on catalase level in the (A) prefrontal
rats after the MWM task. Values are expressed as mean ± SEM (
aP < 0.05, bP < 0.01, cP < 0.001 versus vehicle + scopolamine tre
comparison test).3.8. Catalase activity
One way ANOVA revealed significant effect of treatment on
catalase level in the prefrontal cortex [F(9,50) = 8.76,
P < 0.01], hippocampus [F(9,50) = 2.85, P < 0.01] and stria-




































cortex, (B) hippocampus and (C) striatum of scopolamine-treated
). **P < 0.01 versus vehicle-treated control, aP < 0.05, bP < 0.01,








































cortex, (B) hippocampus and (C) striatum of scopolamine-treated
n= 6). **P < 0.01, ***P < 0.001 versus vehicle-treated control,











































































































Figure 8 Effect of SM and CA on nitrite level in the (A)
prefrontal cortex, (B) hippocampus and (C) striatum of scopo-
lamine-treated rats after the MWM task. Values are expressed as
mean ± SEM (n = 6). **P < 0.01; ***P < 0.01 versus vehicle-
treated control, aP< 0.05; bP < 0.01; cP < 0.001 versus vehicle
+ scopolamine treated (one-way ANOVA followed by Tukey post
hoc multiple comparison test).
36 I.O. Ishola et al.scopolamine injection caused significant decrease (P < 0.001,
P < 0.05) in catalase level in the prefrontal cortex and stria-
tum, respectively, when compared with vehicle control treated
(Fig. 6A–C). Meanwhile, tacrine significantly increased
(P < 0.05) levels of catalase in the prefrontal cortex but not
in the hippocampus and striatum. Moreover, the pretreatment
of rats with SM (50, 100 and 200 mg/kg) significantly increased
[F(3,20) = 14.35, p< 0.001] catalase levels by 0.45, 0.46. 0.52
folds, respectively, in the prefrontal cortex when compared
with vehicle-scopolamine treated group. Similarly, treatment
with CA showed significant increase [F(4,25) = 11.88,
p< 0.001] in catalase levels at 50 mg/kg, 100 mg/kg and
200 mg/kg by 0.45, 0.43, 0.46 folds, respectively. Moreover,
the combination of SM 50 mg/kg and CA 50 mg/kg signifi-
cantly increased [F(4,25) = 11.88, p < 0.0001] catalase levels
by 0.35 folds (Fig. 6A). Pretreatment with SM showed a signif-
icant increase [F(3,20) = 3.651, p<= 0.05] in catalase levels
by 0.74 folds at 100 mg/kg in comparison with scopolamine
treated group. However, CA pretreatment produced no signif-
icant increase in catalase level. Interestingly, a significant
increase [F(4,25) = 9.088, p< 0.001] in catalase levels by
0.67 folds was produced following combination of SM
50 mg/kg and CA 50 mg/kg in comparison with scopolamine
treated group (Fig. 6C).
3.9. SOD activity
One way ANOVA revealed significant effect of treatment on
SOD activity in the prefrontal cortex [F(9,50) = 8.12,
P < 0.01], hippocampus [F(9,50) = 7.51, P < 0.01] and stria-
tum [F(9,50) = 7.72, P < 0.01]. Post hoc analysis showed that
scopolamine injection caused significant decrease (P < 0.01) in
SOD activity by 1.79 and 0.85 folds in the prefrontal cortex
and hippocampus, respectively, when compared with vehicle-
treated control (Fig. 7A–C). The decrease in SOD activity
within the prefrontal cortex and hippocampus was reversed
by the pretreatment of rats with tacrine. In contrast, pretreat-
ment of rats with SM produced no significant change in SOD
activity in the prefrontal cortex but SM (200 mg/kg) treatment
significantly increased the activity of SOD within the hip-
pocampus when compared with vehicle-scopolamine treated
group. Moreover, CA treatment (50 and 200 mg/kg) signifi-
cantly increased [F(3,20) = 7.130, P< 0.001] SOD activity
in the prefrontal cortex compared with vehicle-scopolamine
treated group. In addition, pretreatment of rats with CA (50
and 100 mg/kg) significantly increased [F(4,25) = 3.895,
p< 0.0136] SOD activity in the hippocampus by 1.48 folds
when compared with vehicle-scopolamine treated group. Inter-
estingly, the combination of SM 50 mg/kg and CA 50 mg/kg
increased [F(3,20) = 11.14, p= 0.0002] SOD activity by 0.5
folds versus vehicle-scopolamine group (Fig. 7A and B). In
the striatum, no significant change in SOD activity was
observed in SM and CA pretreated rats but the combination
of SM 50 mg/kg and CA 50 mg/kg increased [F(2,15)
= 10.60, p = 0.0013] SOD activity by 0.61 folds when com-
pared with vehicle-scopolamine treated group (Fig. 7C).
3.10. Nitrite level
One way ANOVA revealed significant effect of treatment on
nitrite generation in the prefrontal cortex [F(9,50) = 8.34,P < 0.01], hippocampus [F(9,50) = 7.47, P < 0.01] and stria-
tum [F(9,50) = 11.22, P < 0.01]. Post hoc analysis showed
that the intraperitoneal injection of scopolamine significantly
(P < 0.01) increased nitrite levels by 2.44, 2.55 and 1.56 folds
in the prefrontal cortex, hippocampus and striatum, respec-
tively, when compared with vehicle-treated control. However,
pretreatment of rats with tacrine attenuated nitrite generation
by 1.23 and 1.61 folds, respectively, in the prefrontal cortex
and hippocampus but no significant change in nitrite level
was seen in the striatum when compared with vehicle-
scopolamine treated group. Similarly, the pretreatment of rats
with SM (50 mg/kg) significantly decreased nitrite level by 1.24
and 1.83 folds in the prefrontal cortex and hippocampus,
respectively, when compared with scopolamine treatment
(Fig. 8A and B). Moreover, pretreatment of rats with CA
(50 and 100 mg/kg) significantly attenuated scopolamine-
induced nitrite generation in the prefrontal cortex, hippocam-
pus and striatum. In addition, the combination of SM 50 mg/
kg and CA 50 mg/kg significantly ameliorated scopolamine-
induced increase in nitrite level in the hippocampus and stria-
tum (Fig. 8A–C).
Cognitive enhancing effect of Spondias mombin and Cola acuminata 374. Discussion
In this study, we demonstrated that the pretreatment of rats
with Spondias mombin or Cola acuminata prevented
scopolamine-induced memory impairment in rats. Moreover,
the combination of Spondias mombin and Cola acuminata pro-
duced synergistic improvement in learning and working mem-
ory in rats without affecting the spontaneous motor activity. It
is of interest to state that the extracts or their combination
improved antioxidant defence system in the prefrontal cortex
and hippocampus of scopolamine treated rats.
Scopolamine, a non-selective muscarinic antagonist induces
dysregulation of the cholinergic neuronal pathway andmemory
circuits in the central nervous system, resulting in serious
impairments in learning, acquisition, and short-term retention
of spatial memory tasks.37 In the present study, we used two
well-characterized memory tasks: Y-maze test and MWM test
in rats to investigate the protective effect of Spondia mombin
and Cola acuminata against scopolamine-induced memory
impairment. Scopolamine is well known for its amnesic effect
in animals and human38,39 and its pretrial administration caused
cognitive impairment in both the Y-maze and MWM tests.8
Scopolamine-induced cognitive dysfunction has been reported
to be associated with impairment in central cholinergic system
which plays an important role in learning and memory.7,40
The Y maze task is a specific and sensitive test of spatial
recognition or working memory in rodents which relies on
an innate tendency of rats to explore a novel environment.32,41
In agreement with previous studies, scopolamine administra-
tion impaired spatial working memory evidenced in the signif-
icant reduction in spontaneous alternation behaviour.32
However, the pretreatment of rats with Spondias mombin or
Cola acuminata as well as their combination significantly
improved spatial working memory evidenced in the increase
in relative proportion of spontaneous alternation percentage
as compared with scopolamine treated rats. Moreover, neither
scopolamine administration nor pretreatment of rats with the
extracts of Spondias mombin or Cola acuminata affected the
total number of arm entries thus ruling out possible psychos-
timulant effect at the tested doses. These results suggested that
the extracts when used alone or in combination could enhance
short term or working memory.32
The Morris water maze learning task is used to assess
hippocampal-dependent spatial learning ability.42 In the pre-
sent study, scopolamine produced impairment of acquisition
and retrieval of memory evidenced in significant in escape
latency. However, pre-trial administration of S. mombin, C.
acuminata or their combination for three consecutive days
before scopolamine injection on day 3 significantly decreased
escape latency time in a non-dose dependent manner from
day 2 to 5. The reduction in escape latency from day to day
reflects learning with respect to reference or long-term mem-
ory. This suggests that S. mombin and C. acuminata signifi-
cantly ameliorated the deficit in long-term memory induced
by scopolamine.
Previous studies showed that scopolamine induced amnesia
is associated with increased oxidative stress in brain.7,39 In the
present study, we found increased oxidative and nitrosative
stresses evidenced in elevated MDA and nitrite levels in the
prefrontal cortex, hippocampus and striatum of
scopolamine-treated rats brain. Scopolamine was also foundto disturb metabolism, especially for low molecular weight
antioxidants such as glutathione, and therefore intensify the
level of lipids peroxidation within the brain,42 which is partic-
ularly vulnerable to reactive oxygen species (ROS) action due
to high abundance of highly oxidizable polyunsaturated fatty
acids. However, the pretreatment of rats with C. acuminata,
S. mombin or their combinations ameliorated scopolamine-
induced increase in MDA and nitrite levels in the prefrontal
cortex. GSH on the other hand provides major protection in
oxidative injury by participating in the cellular defence system
against oxidative damage.43 In this study, scopolamine injec-
tion caused significant decrease in the GSH, catalase and
superoxide dismutase which were reversed by pretreatment
of rats with S. mombin, C. acuminata or their combinations,
which possibly renders them as promising antioxidants. The
nitrite scavenging ability of S. mombin and C. acuminata
extracts further expands their role as potent antioxidants. Fur-
thermore, the results of the DPPH and FRAP assays indicate
potent free radical scavenging effect of S. mombin and C.
acuminata. DPPH is a stable free radical, when antioxidant
reacts with DPPH, the electron is paired off and the DPPH
solution is decolorized. The scavenging activity of the antioxi-
dant or the bleaching of the colour stoichiometrically depends
on the number of electrons taken up. This may be as a result of
the hydrogen donating ability of the phenols in the extracts.
The total phenolic and flavonoid content assays showed that
the extracts are rich in polyphenolic compounds most impor-
tantly, flavonoids. It is presumed that the hydroethanolic
extracts owe their antioxidant activity due to high phenolic
and flavonoid contents.44 Flavonoids have also been reported
to act as acetylcholinesterase inhibitor.45 In addition, the ferric
ion reducing power capacity of the extracts further supports
the potential antioxidant capacity of S. mombin and C. acumi-
nata extracts. The reducing properties are generally connected
with the presence of reductones.45 The ferrous ion increases
lipid oxidation through the breakdown of hydrogen and lipid
peroxides to reactive free radicals via the Fenton reaction. It
can also accelerate peroxidation by decomposing lipid
hydroperoxides into peroxyl and alkoxyl radicals.46 These rad-
icals can themselves attract hydrogen and perpetuate the chain
reaction of lipid peroxidation. Thus, inhibition of lipid perox-
idation by extracts of S. mombin and C. acuminata can be a
fundamental property through which they can mitigate the ini-
tiation and/or propagation of oxidative stress related diseases.
Further study is ongoing in our laboratory to elucidate the
active principles responsible for the observed effect and their
action on cholinergic neurotransmission.
Findings from this study showed that the extracts of Spon-
dias mombin and Cola acuminata possess memory enhancing
effects possibly through enhancement of antioxidant defence
systems. Thus, they could be potential phytotherapeutic agents
in the treatment of dementia of Alzheimer’s type.
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